Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations

作     者：Jill Wykosky Tim Fenton Frank Furnari Webster K. Cavenee 

作者机构：Ludwig Institute for Cancer ResearchUniversity of California San Diego Department of Medicine University of California San Diego 

出 版 物：《Chinese Journal of Cancer》 (Chin. J. Cancer)

年 卷 期：2011年第30卷第1期

页      面：5-12页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by an award from the Goldhirsh Foundation NIH Grant P01-CA95616 NIH(NINDS)Fellowship Award F32NS066519 Fellow Awardfrom the National Foundation for Cancer Research 

主　　题：表皮生长因子受体 靶向治疗 癌症 人类 酪氨酸激酶抑制剂 信号转导通路 恶性肿瘤 临床治疗 

摘      要：Epidermal growth fac tor receptor (EGFR) is one of the most commonly altered genes in human cancer by way of over-expression, amplification, and mutation. Targeted inhibition of EGFR activity suppresses signal transduction pathways which control tumor cell growth, proliferation, and resistance to apoptosis. Small molecule tyrosine kinase inhibitors and monoclonal antibodies are among the most common EGFR-targeting agents and have been used clinically for treating various malignancies. This review discusses the successes and challenges of targeting EGFR in human cancer. The genetic alterations of EGFR tend to occur more often in some solid tumors than others, as do the mechanisms of resistance to targeted inhibition. The clinical and basic science experiences with these agents thus far have important implications for the future of therapeutic targeting of EGFR.